Science of implants

CEREPLAS - CONFIDENTIEL Inhaltsübersicht Cereform Wettbewerbsvorteile ,[object Object],Aufbau des Brustimplantats Cereplas Einführung

CEREPLAS - CONFIDENTIEL ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction

CEREPLAS - CONFIDENTIEL Cereform ® Aufbau des Brustimplantats Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction

CEREPLAS - CONFIDENTIEL Unser Silikongel ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction

CEREPLAS - CONFIDENTIEL ,[object Object],[object Object],[object Object],[object Object],Unser Silikongel Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction ,[object Object],[object Object],[object Object],[object Object],[object Object],Hitze A A A A A B

CEREPLAS - CONFIDENTIEL Cereform Hülle E « enveloppe » layer B « Barrier » layer G Cohesive gel ,[object Object],[object Object],[object Object],[object Object],Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction

CEREPLAS - CONFIDENTIEL Cereform Hülle Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction Barriereschicht 20% Verhindert das Austreten kleinster Partikel aus dem Implantat Silokonhülle Mechanische Eigenschaften: Gegen Bruch, Risse, etc.

CEREPLAS - CONFIDENTIEL Dicke : 600 µ m an der Spitze - 1000 µ m an der Basis CEREFORM HÜLLE ,[object Object],[object Object],[object Object],[object Object],[object Object],Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction Zum Verständnis, CEREFORM Implantate: mehrere DÜNNERE Schichten ( « Buch Effekt»). Die Hülle ist somit nicht dicker! Niedriges Profil Medium Profil Hohes Profil 16 bis 18 Schichten äbhängig von der Projektion 7 Einzelschichten 3 Barriere Schichten 6 Schichten 7 Schichten 8 Schichten

CEREPLAS - CONFIDENTIEL Das Patch  Schwachpunkt der meisten Implantate CEREFORM exclusiv : Dünne Barriere Schicht am Patch Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction

CEREPLAS - CONFIDENTIEL Das Verschlusspatch ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction

CEREPLAS - CONFIDENTIEL ,[object Object],[object Object],[object Object],[object Object],Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction Strenge Qualitätsanforderungen ,[object Object],[object Object],[object Object]

CEREPLAS - CONFIDENTIEL ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Strenge Qualitätsanforderungen Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction

CEREPLAS - CONFIDENTIEL ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction Unsere Wahl der Texturierung ,[object Object],[object Object],Umgekehrte intermediäre Texturierung  Unterbindet dadurch herausragend die Entstehung einer Kapselfibrose

CEREPLAS - CONFIDENTIEL Vergleich Oberflächenstruktur Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction Smooth / micro texture <5µm Intermediate texture Cereform: 35µm Macro texture >100µm Mangelnde Verwachsung mit dem Gewebe Leichter zu entfernen Bester Kompromiss Schwieriger Einzusetzen Schwieriger zu entfernen Schmerzhaft, kann leichter zu einer Kapselfibrose führen Beste Verwachsung mit dem Gewebe

CEREPLAS - CONFIDENTIEL Cereform ®Angebot ,[object Object],[object Object],[object Object],[object Object],Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction ,[object Object]

CEREPLAS - CONFIDENTIEL Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereform ® Angebot:

CEREPLAS - CONFIDENTIEL ,[object Object],[object Object],[object Object],[object Object],Unsere Lebenslange Garantie Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction Cereform ® Garantie:

CEREPLAS - CONFIDENTIEL CEREFORM ® Analyse CEREFORM® Implantate sind seit Februar 2007 auf dem Markt. Seither wurden 85 831 Implantate implantiert. Laut Marktanalyse sind bisher 99 Komplikationen bekannt. Dies entspricht einer Rate von 0,12 %. A breakdown of the complaints is provided in chart below. Cereform competitive advantage Assets Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction

CEREPLAS - CONFIDENTIEL Cereform competitive advantage Differentiation Post market data To keep in mind ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Cereplas Introduction Cereform Arion Allergan Eurosilicone Beschaffen-heit der Hülle Dehnung Minimum 450% 869% 500% 659% 550% Force at rupture 21,5N - 16.9N 14.3N

Science of implants

Recomendados

Recomendados

Mais conteúdo relacionado

Destaque

Destaque (20)

Science of implants